Millions of people with asthma who use blue salbutamol inhalers are being urged to contact their GP following updated guidelines from the National Institute for Health and Care Excellence (NICE). The health body now warns that overuse of these traditional reliever inhalers may actually worsen the condition over time.
New Recommendations for Asthma Treatment
NICE has changed its recommendations after research revealed that blue inhalers only provide temporary relief without addressing the underlying inflammation. The updated guidance advises patients to consider switching to combination inhalers that both treat inflammation and prevent flare-ups while offering immediate symptom relief.
Dr Amina Al-Yassin explained: "They make people feel better, but only briefly. We now know that over time, they are likely to make asthma worse." The warning is supported by evidence linking overuse of salbutamol to a higher risk of asthma attacks, hospital admissions, and even death.
Concerns Over Overuse
Data shows that nearly half of blue inhaler users in England were prescribed more than two inhalers in 2024-25, indicating potential over-reliance. NICE emphasizes that patients should review their asthma management plans with healthcare professionals to ensure optimal treatment.
Combination inhalers, which combine steroids with long-acting medicines in a single device, are now recommended as a first-line treatment. Professor Ewan Maule noted that this upgrade leads to "fewer flare-ups, fewer hospital visits, and better long-term lung health."
What Patients Should Do
Asthma sufferers are encouraged to contact their GP to discuss their current treatment and explore whether a combination inhaler might be more suitable. The goal is to improve overall asthma control and reduce the risks associated with blue inhaler overuse.
